Mounjaro Weight Loss Plateau: Why It Happens and How to Break Through

If you have been taking Mounjaro (tirzepatide) for several weeks and the number on the scale has stopped moving, you are not alone. A weight loss plateau is one of the most common experiences reported by patients on GLP-1 and GIP/GLP-1 receptor agonist therapy. The good news is that a stall on the scale does not necessarily mean the medication has stopped working. In many cases, your body composition is still changing in your favour.

At CutKilo, our doctors see this pattern regularly. Understanding why plateaus happen, and what the clinical evidence actually shows, puts you in a much stronger position to respond effectively rather than feel discouraged.

Yes. Nearly every patient on tirzepatide will experience at least one period where weight loss slows significantly or appears to stop altogether. Clinical trials define a plateau as a weight change of less than five per cent over a 12-week interval. However, research from the SURMOUNT-1 trial shows that even during these periods, fat mass continues to decrease while lean mass is relatively preserved. In other words, the medication is still doing its job; your body is simply recalibrating.

Two distinct physiological processes drive the plateau. The first is metabolic adaptation. As you lose weight, your body requires fewer calories to sustain itself. Basal metabolic rate falls in proportion to the reduction in body mass. On top of that, a phenomenon called adaptive thermogenesis can reduce your energy expenditure by an additional 100 to 300 kilocalories per day beyond what the weight loss alone would predict. This means the caloric deficit that initially drove rapid weight loss gradually narrows until energy intake and expenditure reach a new balance.

The second factor is hormonal recalibration. Weight loss triggers increases in ghrelin (the hunger hormone) and decreases in satiety hormones such as leptin and peptide YY. Although tirzepatide continues to suppress appetite through its dual GIP and GLP-1 receptor activity, the body’s counter-regulatory signals gradually strengthen over time. For many patients, the appetite suppression that felt effortless in the first few months becomes less pronounced as the body adapts.

The SURMOUNT-1 body composition substudy, published in Diabetes, Obesity and Metabolism in 2025, provides reassuring data. Participants taking the highest dose of tirzepatide (15 mg) achieved an average total weight reduction of 21.3 per cent over 72 weeks. Of that reduction, approximately 74 per cent came from fat mass and 26 per cent from lean mass. This ratio is similar to what is seen with diet and exercise alone, which suggests tirzepatide does not cause disproportionate muscle wasting.

Furthermore, reductions in fat-free muscle volume were small and fell within expected ranges based on reference data from the UK Biobank. This is why tracking body composition matters far more than watching the scale during a plateau. You may be losing fat and preserving muscle, which is exactly the outcome you want, even if the total number on the scale barely moves. A DEXA London, CutKilo’s sister service body composition scan at the same 86 Harley Street clinic can show precisely how much fat you are still losing, how much lean mass you are retaining, and whether visceral fat around your organs is continuing to fall.

Before assuming you have hit a genuine plateau, it is worth checking a few things. Weight can fluctuate by one to two kilograms day to day because of fluid shifts, hormonal cycles, bowel transit, and sodium intake. A single week of unchanged weight is not a plateau. Most clinicians would not diagnose a true stall until the scale has remained within the same narrow range for at least three to four consecutive weeks.

In addition, consider non-scale indicators. Are your clothes fitting differently? Has your waist circumference decreased? Do you have more energy during exercise? These signs often point to ongoing fat loss combined with muscle preservation, which is a far better outcome than rapid weight loss that includes significant lean mass reduction.

If you have genuinely stalled for more than four weeks, several approaches are supported by clinical evidence and recommended by obesity medicine specialists.

Increase your protein intake. The European Association for the Study of Obesity recommends consuming 1.0 to 1.2 grams of protein per kilogram of body weight daily during active weight loss with GLP-1 therapy. Protein supports muscle protein synthesis, increases the thermic effect of feeding, and improves satiety. If you have not already read our guide on protein on Mounjaro, it covers practical meal strategies in detail.

Add or adjust resistance training. Strength training two to three times per week is one of the most effective interventions for preserving lean mass during weight loss. Muscle is metabolically active tissue; maintaining it helps offset the drop in basal metabolic rate that drives the plateau. Even bodyweight exercises or resistance bands can make a meaningful difference if you are not currently training.

Review your calorie intake honestly. As your weight drops, so does your calorie requirement. A meal pattern that produced a deficit at 100 kilograms may be at maintenance level by the time you reach 85 kilograms. Recalculating your target intake based on your current weight can restore the deficit needed to resume progress.

Discuss dose adjustment with your prescriber. NICE guidance (TA1026) recommends reviewing treatment if less than five per cent of initial body weight has been lost after six months on the highest tolerated dose. For patients on lower doses who have plateaued, titrating up to the next increment often restarts weight loss by providing a stronger receptor signal. At CutKilo, dose adjustments are always clinician-led and based on your individual response, side-effect profile, and clinical targets.

Prioritise sleep and manage stress. Chronic sleep deprivation increases cortisol and ghrelin, both of which promote fat storage and hunger. Aiming for seven to nine hours of quality sleep per night supports the hormonal environment needed for continued fat loss. Similarly, sustained psychological stress can raise cortisol levels enough to blunt the metabolic benefits of tirzepatide.

Most plateaus resolve within two to six weeks once lifestyle adjustments or dose changes are made. However, there are situations that warrant a conversation with your prescribing doctor. If your weight has been static for more than eight weeks despite optimised protein, exercise, and dose, your clinician may want to check thyroid function, cortisol levels, or screen for other endocrine conditions that can independently stall weight loss.

It is also worth noting that some patients reach a new set point where their body resists further weight loss. This is not a failure of the medication; rather, it reflects the physiological limits of pharmacotherapy alone. Continued treatment at this stage is still valuable because it helps maintain the weight already lost. The SURMOUNT-4 trial demonstrated that patients who discontinued tirzepatide after 36 weeks regained approximately two-thirds of the weight they had lost, whereas those who continued treatment maintained their results.

A weight loss plateau on Mounjaro is not a sign that the medication has failed. It is a predictable phase driven by metabolic adaptation and hormonal recalibration. The SURMOUNT-1 data confirms that fat loss continues to outpace lean mass loss throughout treatment, meaning your body composition is likely still improving even when the scale is not moving. Focus on protein intake, resistance training, honest calorie review, and open communication with your prescriber. With the right adjustments, most patients move through the plateau and resume meaningful progress.

How long does a Mounjaro weight loss plateau usually last? Most plateaus last between two and six weeks. If weight has not changed for more than eight weeks despite lifestyle and dose optimisation, speak with your prescribing doctor to rule out other medical causes.

Should I increase my Mounjaro dose if I hit a plateau? Dose increases should only be made under medical supervision. If you are not yet on the highest tolerated dose, your prescriber may recommend titrating up. NICE recommends reviewing treatment effectiveness after six months on the maximum tolerated dose.

Can I still be losing fat even if my weight stays the same? Yes. Body composition changes often continue during a scale plateau. You may be losing fat while preserving or even slightly increasing muscle mass, particularly if you are doing resistance training. A DEXA body composition scan is the most accurate way to confirm this.

Is it normal to stop losing weight after the first few months on Mounjaro? Entirely normal. The initial rapid weight loss phase is driven by significant appetite suppression and a large caloric deficit. As your body adapts and your calorie needs decrease, the rate of loss naturally slows. This does not mean the treatment has stopped working.

What percentage of weight loss on Mounjaro comes from muscle? According to the SURMOUNT-1 body composition substudy, approximately 26 per cent of total weight lost comes from lean mass and 74 per cent from fat mass. This ratio is consistent with what is seen in non-pharmacological weight loss interventions.